RecruitingPhase 4NCT07598214

Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients

Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial

Sponsor

Beni-Suef University

Enrollment

100 participants

Start Date

Feb 3, 2025

Study Type

INTERVENTIONAL

Conditions

Cancer Patients

Summary

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying diosmin/hesperdin for people with cancer patients. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTdiosmin/hesperdin

combination of Diosmin and Hesperidin

Locations(1)

Faculty of Medicine

Banī Suwayf, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07598214

Related Trials

A Study of an Anxiety Intervention for Latino/Latina/Hispanic Older Adults With Cancer and Their Caregivers

NCT063057417 locations

A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain

NCT074478567 locations